Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

741. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. (Abstract)

medications was also reduced across all illness syndromes. Vaccine recipients were more likely to experience runny nose or sore throat during the first 7 days after vaccination, but serious adverse events between the groups were not significantly different. The match between the type A(H3N2) vaccine strain and the predominant circulating virus strain (A/Sydney/05/97[H3N2]) for the 1997-1998 season was poor, suggesting that LAIV provided substantial cross-protection against this variant influenza A virus (...) Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. Influenza virus is a major cause of illness, disruption to daily life, and increased use of health care in all age groups.To assess the safety and effectiveness of intranasally administered trivalent, live, attenuated influenza virus (LAIV) vaccine for reducing illness, absenteeism, and health care use among healthy, working adults.Randomized, double-blind, placebo

1999 JAMA Controlled trial quality: predicted high

742. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. (Abstract)

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. The neuraminidase inhibitor zanamivir, a sialic acid analog administered directly to the respiratory tract, has been demonstrated in clinical studies to be effective in treatment of type A and B influenza. It has also been shown to prevent influenza infection and disease in an experimental model.To examine the efficacy of zanamivir, administered once daily, in the prevention of influenza infection (...) and disease.Double-blind, randomized, placebo-controlled trial.Two midwestern university communities.A total of 1107 healthy adults (mean age [range], 29 [18-69] years) were recruited in November 1997, before the influenza season.At the start of the influenza outbreak, 554 subjects were randomized to receive placebo and 553 to receive zanamivir. The drug, 10 mg once per day, or identical placebo was administered by oral inhalation for a 4-week period.Illness occurrence was recorded by participants daily

1999 JAMA Controlled trial quality: predicted high

743. Meta-analysis of effectiveness of interventions to increase influenza immunization rates among high-risk population groups

to reach those clients who do not routinely visit a health clinic during the influenza vaccination season. Provider incentives and/or enhanced patient access through walk-in clinics, free vaccination, satellite vaccination sites, or the scheduling of annual physicals during the flu season are possible strategies for increasing patient provider contact. CRD commentary An average review of the area. The literature search was limited to one database (MEDLINE) and only studies published in English were (...) Meta-analysis of effectiveness of interventions to increase influenza immunization rates among high-risk population groups Meta-analysis of effectiveness of interventions to increase influenza immunization rates among high-risk population groups Meta-analysis of effectiveness of interventions to increase influenza immunization rates among high-risk population groups Sarnoff R, Rundall T Authors' objectives To assess the impact of three types of intervention on influenza immunisation uptake

1999 DARE.

744. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies

Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies Beyer W E, de Bruijn I A, Palache A M, Westendorp R G, Osterhaus A D Authors' objectives To determine whether the protection of influenza vaccine decreases when (...) vaccination is repeated annually. Searching The authors searched MEDLINE from 1966 to 1997 using the terms 'influenza', and 'vaccine' or 'vaccination'. The search strategy was limited to human studies and included articles in English, Dutch, German, French, Spanish, Italian, and Russian. Cross-references in already identified articles were included. Study selection Study designs of evaluations included in the review Field studies that presented data on influenza-related morbidity or mortality in groups

1999 DARE.

745. Economic evaluation of influenza vaccination: assessment for The Netherlands

Economic evaluation of influenza vaccination: assessment for The Netherlands Economic evaluation of influenza vaccination: assessment for The Netherlands Economic evaluation of influenza vaccination: assessment for The Netherlands Postma M J, Bos J M, van Gennep M, Jager J C, Baltussen R, Sprenger M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Influenza vaccination. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Elderly individuals aged 65 years and older. Setting Primary care. The study was carried out in The Netherlands. Dates to which data relate Effectiveness data were collected from studies published between 1980 and 1997. Resource use data were

1999 NHS Economic Evaluation Database.

746. Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine: estimating cost-effectiveness using decision analysis

Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine: estimating cost-effectiveness using decision analysis Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine: estimating cost-effectiveness using decision analysis Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine: estimating cost-effectiveness using decision analysis Fendrick A M, Lee J H, LaBarge C, Glick H A Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A combination haemophilus influenzae type b (Hib) vaccine. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population A representative cohort

1999 NHS Economic Evaluation Database.

747. Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain

Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain Jimenez F J, Guallar-Castillon P, Terres C R, Guallar E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Universal vaccine against Haemophilus influenzae type b (Hib) in children. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Spanish children under 1 year of age. Setting Primary care. The economic study was carried out in Spain. Dates to which data relate Effectiveness data were collected from studies

1999 NHS Economic Evaluation Database.

748. Economic impact of providing workplace influenza vaccination: a model and case study application at a Brazilian pharma-chemical company

Economic impact of providing workplace influenza vaccination: a model and case study application at a Brazilian pharma-chemical company Economic impact of providing workplace influenza vaccination: a model and case study application at a Brazilian pharma-chemical company Economic impact of providing workplace influenza vaccination: a model and case study application at a Brazilian pharma-chemical company Burckel E, Ashraf T, Galvao de Sousa Filho J P, Neto E F, Guarino H, Yauti C, de Barros (...) Barreto F, Champion L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Influenza vaccination for healthy adult workers. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population 4,030

1999 NHS Economic Evaluation Database.

749. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years

The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years Nichol K L, Goodman M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Influenza vaccination was given to members of a managed care organisation during 6 consecutive influenza seasons (October to December). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis and cost-benefit analysis. Study population The study population comprised members of a health

1999 NHS Economic Evaluation Database.

750. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. (Abstract)

Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. The cost of Haemophilus influenzae type b (Hib) conjugate vaccines has limited their use in non-industrialised countries. To identify more economical vaccination schedules, we carried out a randomised trial of the immunogenicity of alternative regimens to the standard three-dose series.627 Chilean infants were randomly allocated to one of four

1998 Lancet Controlled trial quality: uncertain

751. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. (Abstract)

Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. Despite current recommendations, many people with asthma do not receive annual vaccination against influenza, partly because of concern that vaccine may trigger exacerbations. Colds can trigger exacerbations, which may be mistaken for vaccine-related adverse events. We undertook a double-blind placebo-controlled multicentre crossover study to assess the safety of influenza (...) three; binomial test p=0.51), although the difference for PEF decreases of more than 30% approached significance (five vs none; binomial test, p=0.06). This association was confined to first-time vaccinees.Our findings indicate that pulmonary-function abnormalities may occur as a complication of influenza vaccination. However, the risk of pulmonary complications is very small and outweighed by the benefits of vaccination.

1998 Lancet Controlled trial quality: predicted high

752. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. (Abstract)

Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Influenza affects many people worldwide each year and has many troublesome symptoms. We investigated the efficacy and safety of the inhaled antiviral agent zanamivir as a treatment for influenza A and B infection.In a randomised, double-blind, placebo-controlled trial, we recruited 455 patients aged (...) 12 years and older with influenza-like symptoms of 36 h duration or less who lived in Australia, New Zealand, and South Africa. Eligible patients were randomly assigned 10 mg inhaled zanamivir (n=227) or placebo (n=228) twice daily for 5 days. All patients recorded symptoms on diary cards four times daily during treatment and twice daily for 9 days after treatment. We analysed all patients by intention to treat, influenza-positivity, and high risk of developing complications.Compared with placebo

1998 Lancet Controlled trial quality: predicted high

753. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature

Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature Beyer W E, Palache A M (...) , Osterhaus A D Authors' objectives To compare the serology and reactogenicity between influenza subunit (SU) vaccines and whole virus (WV) or split (SPL) vaccines. Searching MEDLINE, EMBASE and BIOSIS Previews were searched from January 1975 to December 1995 using the combination 'influenza' (without Haemophilus influenzae) and 'vaccin..' and 'subunit' or 'subviron'. The search was started in 1975 since the key articles on the preparation of modern SU vaccines were published in 1975 and 1976. Four papers

1998 DARE.

754. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, the Netherlands

Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, the Netherlands Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, the Netherlands Is immunising all patients with chronic lung disease in the community against influenza (...) An influenza vaccination programme to prevent complications in a general practice based cohort of adult patients with a chronic lung disease. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Adult patients with a chronic lung disease. Setting Primary care. The economic study was carried out in the Netherlands. Dates to which data relate Effectiveness and resource use data were collected between October 1995 and March 1996. The price year was 1995

1998 NHS Economic Evaluation Database.

755. Economic evaluation of general childhood vaccination against Haemophilus influenzae type B in Sweden

Economic evaluation of general childhood vaccination against Haemophilus influenzae type B in Sweden Economic evaluation of general childhood vaccination against Haemophilus influenzae type B in Sweden Economic evaluation of general childhood vaccination against Haemophilus influenzae type B in Sweden Garpenholt O, Silfverdal S A, Levin L A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology General childhood vaccination against Haemophilus influenzae type B (HiB). Type of intervention Primary prevention. Economic study type Cost-benefit analysis. Study population The study population comprised children aged 0-4 years. Setting The setting was primary care. The economic study was carried out in Sweden. Dates to which data relate

1998 NHS Economic Evaluation Database.

756. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. (Abstract)

Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Inclusion of new vaccines in vaccination programmes for children would be easier if they could be combined with existing vaccines. Vaccines containing acellular pertussis in the diphtheria/tetanus/pertussis (DTP-a) combination are expected to replace the conventional whole-cell vaccines (DTP-w). We tested the immunogenicity and safety (...) of a combination of DTP-a with the Haemophilus influenzae type b (Hib) conjugate of Hib capsular polysaccharide and tetanus toxid (PRP-T), and inactivated poliovirus vaccine (i.p.v.).120 infants were enrolled and randomised to four groups to receive DTP-a at ages 2, 4, and 6 months. At 4 and 6 months they also received Hib conjugate and i.p.v., either as separate injections or mixed with DTP-a. All injections were given intramuscularly in the anterolateral area of the thigh. Any reactions after each

1997 Lancet Controlled trial quality: uncertain

757. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. (Abstract)

Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. In developing countries, pneumonia and meningitis due to Haemophilus influenzae type b (Hib) are common in children under age 12 months and the mortality from meningitis is high. Protein-polysaccharide conjugate vaccines have brought Hib disease under control in industrialised countries. We did a double-blind randomised trial

1997 Lancet Controlled trial quality: predicted high

758. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. Full Text available with Trip Pro

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. The sialic acid analogue zanamivir (GG167) is a selective inhibitor of influenza A and B virus neuraminidases. These viral enzymes are essential for the release of virus from infected cells, and they may also reduce the inactivation of virus by respiratory secretions. When administered experimentally directly to the respiratory tract, zanamivir has potent (...) antiviral effects. We assessed the therapeutic activity of zanamivir in adults with acute influenza.We conducted separate randomized, double-blind studies in 38 centers in North America and 32 centers in Europe during the influenza season of 1994-1995. A total of 417 adults with influenza-like illness of < or =48 hours' duration were randomly assigned to one of three treatments: 6.4 mg of zanamivir by intranasal spray plus 10 mg by inhalation, 10 mg of zanamivir by inhalation plus placebo spray

1997 NEJM Controlled trial quality: uncertain

759. [Cost-effectiveness of influenza vaccine in The Netherlands]

[Cost-effectiveness of influenza vaccine in The Netherlands] Kosteneffectiviteit van influenzavaccinatie in Nederland [Cost-effectiveness of influenza vaccine in The Netherlands] Kosteneffectiviteit van influenzavaccinatie in Nederland [Cost-effectiveness of influenza vaccine in The Netherlands] Reinders A, Postma M J, Govaert T M, Sprenger M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Influenza vaccination. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population People aged 65 or over and young people at risk of influenza in the Netherlands. Setting Community and primary care. The study was carried out by the National Institue of Public Health and Environment

1997 NHS Economic Evaluation Database.

760. Influenza vaccination among healthy employees: a cost-benefit analysis

Influenza vaccination among healthy employees: a cost-benefit analysis Influenza vaccination among healthy employees: a cost-benefit analysis Influenza vaccination among healthy employees: a cost-benefit analysis Kumpulainen V, Makela M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Influenza vaccination of healthy working adults (healthy municipal homemakers). The vaccine offered was the Connaught inactivated trivalent split influenza vaccine (Fluzone) containing two influenza A components and one influenza B component. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study looked at healthy adults working as municipal homemakers caring for elderly people

1997 NHS Economic Evaluation Database.